The oncology landscape is rapidly evolving with the rise of oncolytic virus (OV) therapies—next-generation immunotherapies designed to selectively destroy cancer cells while activating the body’s immune defenses. Offering a novel approach to treating malignancies, these engineered viruses are showing promise in a range of tumor types, from melanoma to pancreatic cancer. DelveInsight’s latest report, Oncolytic Read.